Imneskibart is under clinical development by Aulos Bioscience and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imneskibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Imneskibart overview

imneskibart (AU-007) is development for the treatment of solid tumor, melanoma, renal cell cancer, Merkel cell carcinoma, colorectal cancer, non-small cell lung cancer, cutaneous squamous cell carcinoma (cscc), bladder cancer, head and neck cancer squamous cell carcinoma, pancreatic cancer, uveal melanoma, acral lentiginous melanoma, leiomyosarcoma, uterine cancer and urothelial cancer. It acts by targeting the CD25-binding epitopes of interleukin 2 (IL-2), sparing the binding to the CD122/132-binding epitope. It is being developed based on artificial intelligence.

Aulos Bioscience overview

Aulos Bioscience, an ATP company is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. The company is developing unique IL-2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors. Aulos Bioscience is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Imneskibart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.